Speaker Profile
Ph.D., Co-Founder & CSO, BioSymetrics (Lunai)
Biography
Dr. Musso has a background in molecular genetics (PhD), and did post-doctoral work at Harvard Medical School and Brigham and Women's Hospital on computational and developmental biology. He spent time at a start-up working on real-time machine learning, before joining with others to start BioSymetrics with the aim of tackling the specific challenges of working with biomedical data. He was named one of the top 100 leaders in AI and drug discovery, has authored over 30 peer reviewed publications on AIML and biology.
Talk
Closing the loop: Coupling AI with In vivo validation
AI models are accelerating target and compound discovery, but translation remains a bottleneck. We present a closed-loop platform integrating predictive AI with high-throughput in vivo validation using disease models relevant to neurological disease. Case studies demonstrate how this approach improves hit prioritization, enhances biological relevance, and increases success rates in drug development.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
